Ranibizumab for Macular Edema following Central Retinal Vein Occlusion: Six-Month Primary End Point Results of a Phase III Study
Top Cited Papers
- 30 June 2010
- journal article
- research article
- Published by Elsevier BV in Ophthalmology
- Vol. 117 (6), 1124-1133.e1
- https://doi.org/10.1016/j.ophtha.2010.02.022
Abstract
No abstract availableKeywords
This publication has 27 references indexed in Scilit:
- A Randomized Trial Comparing the Efficacy and Safety of Intravitreal Triamcinolone With Observation to Treat Vision Loss Associated With Macular Edema Secondary to Central Retinal Vein OcclusionJAMA Ophthalmology, 2009
- Ranibizumab for the Treatment of Macular Edema Associated with Perfused Central Retinal Vein OcclusionsOphthalmology, 2008
- Ranibizumab for Neovascular Age-Related Macular DegenerationThe New England Journal of Medicine, 2006
- ONE-YEAR SAFETY AND EFFICACY OF INTRAVITREAL TRIAMCINOLONE ACETONIDE FOR THE MANAGEMENT OF MACULAR EDEMA SECONDARY TO CENTRAL RETINAL VEIN OCCLUSIONRetina, 2006
- VENOUS OCCLUSIVE DISEASE: MANAGEMENT 25 YEARS AGORetina, 2006
- RADIAL OPTIC NEUROTOMY FOR CENTRAL RETINAL VEIN OCCLUSIONRetina, 2001
- Vascular endothelial growth factor upregulation in human central retinal vein occlusionOphthalmology, 1998
- The Biology of Vascular Endothelial Growth FactorEndocrine Reviews, 1997
- Dynamic balanced randomization for clinical trialsStatistics in Medicine, 1993
- Die spontane Thrombose der Vena centralis des OpticusAlbrecht von Graefes Archiv für Ophthalmologie, 1878